# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Explorative Formulation of Insulin Degludec

> **NCT01865279** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 64 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** insulin degludec
- **DRUG:** placebo
- **DRUG:** insulin degludec
- **DRUG:** isophane human insulin

## Key facts

- **NCT ID:** NCT01865279
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2006-04
- **Final completion:** 2006-04
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2015-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01865279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01865279, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Explorative Formulation of Insulin Degludec". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01865279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*